See up to 3 months of IBRX. The 7-day demo opens the 1M and 3M ranges and puts IBRX on your watchlist.
Start 7-day demoLatest IBRX insider trades
Barry J. Simon - DirectorOpen-market sale$269K
Cheryl Cohen - DirectorOpen-market sale$851K- Cheryl Cohen - DirectorOpen-market sale$1.25M
- Christobel Selecky - DirectorOpen-market sale$1.44M
- Christobel Selecky - DirectorOpen-market sale$862K
- Christobel Selecky - DirectorOpen-market sale$9K
- Barry J. Simon - DirectorOpen-market sale$197K
- Barry J. Simon - DirectorOpen-market sale$165K
About ImmunityBio, Inc. (IBRX)
ImmunityBio, Inc. files with the SEC under CIK 0001326110 and is classified as biological products (no diagnostic substances). It is grouped with Health Care companies on this site.
IBRX Form 4 activity by transaction type, last 90 days
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 2 | 106,056 | $1.12M |
| Option exercise | 2 | 111,958 |
Dollar totals cover purchases and sales only (codes P and S). Grants, option exercises, gifts and tax withholding are counted in shares, because none of them is a trade at a market price.
IBRX insider transactions (Form 4)
8530 Form 4 filings on record, the earliest from Dec 12, 2024, newest first.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Barry J. Simon - Director | Open-market sale | Common Stock | 25,000 | $10.75 footnote F2 | $269K | |
| ||||||
| Cheryl Cohen - Director | Option exercise | Common Stock | 55,979 | $2.98 | $167K | |
| Cheryl Cohen - Director | Open-market sale | Common Stock | 81,056 | $10.50 | $851K | |
| Cheryl Cohen - Director | Option exercise | Stock Option (right to buy) | 55,979 | $0.00 | - | |
| Cheryl Cohen - Director | Option exercise | Common Stock | 55,979 | $2.98 | $167K | |
| Cheryl Cohen - Director | Option exercise | Stock Option (right to buy) | 55,979 | $0.00 | - | |
| Cheryl Cohen - Director | Open-market sale | Common Stock | 131,210 | $9.50 footnote F2 | $1.25M | |
| ||||||
| Christobel Selecky - Director | Option exercise | Common Stock | 35,064 | $2.98 | $104K | |
| Christobel Selecky - Director | Option exercise | Common Stock | 124,414 | $2.99 | $372K | |
| Christobel Selecky - Director | Option exercise | Stock Option (right to buy) | 35,064 | $0.00 | - | |
| Christobel Selecky - Director | Option exercise | Stock Option (right to buy) | 124,414 | $0.00 | - | |
| Christobel Selecky - Director | Open-market sale | Common Stock | 159,478 | $9.02 footnote F2 | $1.44M | |
| ||||||
| Christobel Selecky - Director | Option exercise | Common Stock | 32,173 | $2.98 | $96K | |
| Christobel Selecky - Director | Option exercise | Common Stock | 33,549 | $2.99 | $100K | |
| Christobel Selecky - Director | Option exercise | Common Stock | 30,000 | $2.84 | $85K | |
| Christobel Selecky - Director | Option exercise | Common Stock | 700 | $2.98 | $2K | |
| Christobel Selecky - Director | Option exercise | Common Stock | 300 | $2.99 | $897 | |
| Christobel Selecky - Director | Option exercise | Stock Option (right to buy) | 32,173 | $0.00 | - | |
| Christobel Selecky - Director | Option exercise | Stock Option (right to buy) | 33,549 | $0.00 | - | |
| Christobel Selecky - Director | Option exercise | Stock Option (right to buy) | 30,000 | $0.00 | - | |
| Christobel Selecky - Director | Option exercise | Stock Option (right to buy) | 700 | $0.00 | - | |
| Christobel Selecky - Director | Option exercise | Stock Option (right to buy) | 300 | $0.00 | - | |
| Christobel Selecky - Director | Open-market sale | Common Stock | 95,722 | $9.01 footnote F2 | $862K | |
| Christobel Selecky - Director | Open-market sale | Common Stock | 1,000 | $9.00 | $9K | |
| ||||||
| Barry J. Simon - Director | Open-market sale | Common Stock | 25,000 | $7.88 footnote F2 | $197K | |
| ||||||
| Michael D. Blaszyk - Director | Grant or award | Stock Option (right to buy) | 65,600 | $0.00 | - | |
| Bruce Wendel - Director | Grant or award | Stock Option (right to buy) | 65,600 | $0.00 | - | |
 Linda Maxwell - Director | Grant or award | Stock Option (right to buy) | 65,600 | $0.00 | - | |
| Wesley Clark - Director | Grant or award | Stock Option (right to buy) | 65,600 | $0.00 | - | |
| Cheryl Cohen - Director | Grant or award | Stock Option (right to buy) | 65,600 | $0.00 | - | |
| Christobel Selecky - Director | Grant or award | Stock Option (right to buy) | 65,600 | $0.00 | - | |
| Barry J. Simon - Director | Open-market sale | Common Stock | 23,033 | $7.18 footnote F2 | $165K | |
| ||||||
| Patrick Soon-Shiong - Officer | Other | Common Stock | 4,606,596 | $5.43 | $25.00M | |
| Patrick Soon-Shiong - Officer | Other | Second Amended and Restated Convertible Promissory Note | 0 | $0.00 | - | |
| Barry J. Simon - Director | Open-market sale | Common Stock | 75,000 | $12.01 footnote F2 | $901K | |
| ||||||
| Christobel Selecky - Director | Option exercise | Common Stock | 25,000 | $2.98 | $75K | |
| Christobel Selecky - Director | Open-market sale | Common Stock | 25,000 | $10.00 | $250K | |
| Christobel Selecky - Director | Option exercise | Stock Option (right to buy) | 25,000 | $0.00 | - | |
| David C. Sachs - Officer | Option exercise | Common Stock | 40,650 | $0.00 | - | |
| David C. Sachs - Officer | Tax withholding / forfeiture | Common Stock | 20,682 | $8.70 footnote F2 | $180K | |
| David C. Sachs - Officer | Option exercise | Restricted Stock Units | 40,650 | $0.00 | - | |
| ||||||
| Patrick Soon-Shiong - Officer | Option exercise | Common Stock | 114,329 | $0.00 | - | |
| Patrick Soon-Shiong - Officer | Tax withholding / forfeiture | Common Stock | 58,170 | $8.70 footnote F2 | $506K | |
| Patrick Soon-Shiong - Officer | Option exercise | Restricted Stock Units | 114,329 | $0.00 | - | |
| ||||||
| Regan J. Lauer - Officer | Option exercise | Common Stock | 4,065 | $0.00 | - | |
| Regan J. Lauer - Officer | Tax withholding / forfeiture | Common Stock | 1,673 | $8.70 footnote F2 | $15K | |
| Regan J. Lauer - Officer | Option exercise | Restricted Stock Units | 4,065 | $0.00 | - | |
| ||||||
| Richard Adcock - Officer | Option exercise | Common Stock | 152,439 | $0.00 | - | |
| Richard Adcock - Officer | Tax withholding / forfeiture | Common Stock | 77,560 | $8.70 footnote F2 | $675K | |
| Richard Adcock - Officer | Option exercise | Restricted Stock Units | 152,439 | $0.00 | - | |
| ||||||
| Barry J. Simon - Director | Open-market sale | Common Stock | 10,000 | $9.25 | $93K | |
| Barry J. Simon - Director | Option exercise | Common Stock | 15,243 | $0.00 | - | |
| Barry J. Simon - Director | Tax withholding / forfeiture | Common Stock | 6,026 | $8.70 footnote F3 | $52K | |
| Barry J. Simon - Director | Open-market sale | Common Stock | 165,000 | $10.25 footnote F4 | $1.69M | |
| Barry J. Simon - Director | Option exercise | Restricted Stock Units | 15,243 | $0.00 | - | |
| ||||||
| Patrick Soon-Shiong - Officer | Option exercise | Common Stock | 274,122 | $0.00 | - | |
| Patrick Soon-Shiong - Officer | Tax withholding / forfeiture | Common Stock | 118,560 | $6.93 footnote F2 | $822K | |
| Patrick Soon-Shiong - Officer | Option exercise | Restricted Stock Units | 274,122 | $0.00 | - | |
| ||||||
| David C. Sachs - Officer | Option exercise | Common Stock | 82,236 | $0.00 | - | |
| David C. Sachs - Officer | Tax withholding / forfeiture | Common Stock | 42,643 | $6.93 footnote F2 | $296K | |
| David C. Sachs - Officer | Option exercise | Restricted Stock Units | 82,236 | $0.00 | - | |
| ||||||
| Regan J. Lauer - Officer | Option exercise | Common Stock | 5,482 | $0.00 | - | |
| Regan J. Lauer - Officer | Tax withholding / forfeiture | Common Stock | 2,257 | $6.93 footnote F2 | $16K | |
| Regan J. Lauer - Officer | Option exercise | Restricted Stock Units | 5,482 | $0.00 | - | |
| ||||||
| Richard Adcock - Officer | Option exercise | Common Stock | 274,122 | $0.00 | - | |
| Richard Adcock - Officer | Tax withholding / forfeiture | Common Stock | 140,048 | $6.93 footnote F2 | $971K | |
| Richard Adcock - Officer | Option exercise | Restricted Stock Units | 274,122 | $0.00 | - | |
| ||||||
| Barry J. Simon - Director | Open-market sale | Common Stock | 76,967 | $6.54 | $503K | |
| Barry J. Simon - Director | Open-market sale | Common Stock | 75,000 | $7.88 footnote F2 | $591K | |
| ||||||
| Christobel Selecky - Director | Option exercise | Common Stock | 50,000 | $2.98 | $149K | |
| Christobel Selecky - Director | Option exercise | Common Stock | 25,000 | $2.98 | $75K | |
| Christobel Selecky - Director | Open-market sale | Common Stock | 50,000 | $5.00 | $250K | |
| Christobel Selecky - Director | Open-market sale | Common Stock | 25,000 | $7.51 footnote F2 | $188K | |
| Christobel Selecky - Director | Option exercise | Stock Option (right to buy) | 50,000 | $0.00 | - | |
| Christobel Selecky - Director | Option exercise | Stock Option (right to buy) | 25,000 | $0.00 | - | |
| ||||||
| Bruce Wendel - Director | Grant or award | Stock Option (right to buy) | 146,020 | $0.00 | - | |
| Regan J. Lauer - Officer | Option exercise | Common Stock | 21,031 | $0.00 | - | |
| Regan J. Lauer - Officer | Tax withholding / forfeiture | Common Stock | 7,503 | $2.87 | $22K | |
| Regan J. Lauer - Officer | Option exercise | Restricted Stock Units | 21,031 | $0.00 | - | |
| Patrick Soon-Shiong - Officer | Other | Common Stock | 103,710,088 | $1.94 | $200.68M | |
| Patrick Soon-Shiong - Officer | Other | Common Stock | 13,475,172 | $2.28 | $30.72M | |
| Patrick Soon-Shiong - Officer | Other | Convertible Promissory Note | 0 | $0.00 | - | |
| Patrick Soon-Shiong - Officer | Other | Convertible Promissory Note | 0 | $0.00 | - | |
| Patrick Soon-Shiong - Officer | Other | Amended and Restated Promissory Note | 0 | $0.00 | - | |
| Patrick Soon-Shiong - Officer | Other | Second Amended and Restated Convertible Promissory Note | 0 | $505,000,000.00 | - | |
Item 2.02, 9.01
Item 7.01, 9.01
Item 5.07, 9.01
Item 1.01, 7.01, 9.01
Item 2.02, 9.01
Recent IBRX Form 144 notices of proposed sale
3An insider files Form 144 before selling restricted or control stock. It announces a planned sale. If the sale goes ahead, it shows up later on a Form 4.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Simon Barry J. | Officer, Director | 560,000 | $7.66M | View on EDGAR | |
| CHERYL COHEN | Director | 81,056 | $752K | View on EDGAR | |
| - | - | - | - | View on EDGAR |
Stock trades in IBRX disclosed by members of the U.S. House in the last 12 months, newest first. Values are the ranges as filed.
| Member | Type | Traded | Disclosed | Value range | Owner | Days to disclose | Filing |
|---|---|---|---|---|---|---|---|
 Lisa C. McClainRepublican, MI-09 | Purchase | $1,001 to $15,000 | Spouse | 14 days | Original filing | ||
| Lisa C. McClainRepublican, MI-09 | Purchase | $1,001 to $15,000 | Spouse | 12 days | Original filing |
House of Representatives Periodic Transaction Reports from 2024. Senate filings are not included yet. The full history of IBRX beside its insider purchases is in the Congress Tracker.
IBRX insider trading FAQ
What is the latest insider trade for IBRX?
ImmunityBio, Inc. (IBRX) had 2 insider filings in the last 90 days, with the most recent on 2026-10-06. The full record for IBRX runs to 30 Form 4 filings, the earliest from 2024-12-12. InsiderAlpha adds new Form 4, Form 144 and 8-K filings as they arrive from SEC EDGAR.
How many insiders are buying IBRX stock?
No insider purchases of IBRX were filed in the last 90 days.
How many insiders are selling IBRX stock?
2 insider sales of IBRX were filed in the last 90 days, totaling $1.12M.
Where can I see IBRX SEC filings (Form 4, 10-K, 10-Q, 8-K)?
This page collects IBRX Form 4 insider transactions, Form 144 sale notices and 8-K filings in one place. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
More Health Care companies with insider activity
Recent insider filings
10The EDGAR links open each original Form 4, so you can check any number on this page against the filing it came from.
- - Barry J. Simon view on EDGAR
- - Cheryl Cohen view on EDGAR
- - Cheryl Cohen view on EDGAR
- - Christobel Selecky view on EDGAR
- - Christobel Selecky view on EDGAR
- - Barry J. Simon view on EDGAR
- - Michael D. Blaszyk view on EDGAR
- - Bruce Wendel view on EDGAR
- - Linda Maxwell view on EDGAR
- - Wesley Clark view on EDGAR
Related companies with recent insider activity
Learn more
- Insider selling: signal or noise?
- Why most insider sales are routine, and the few patterns worth a second look.
- Form 144 vs Form 4
- A Form 144 announces a planned sale; the Form 4 reports it after it happens.
- Insider activity in Health Care
- Where IBRX's peers are being bought and sold.
- Every recent Form 4
- The market-wide feed, updated as filings arrive from SEC EDGAR.
Follow IBRX with a 7-day demo
- IBRX on your watchlist
- Every IBRX Form 4 filing on record
- Up to 3 months of IBRX price history
- The daily trading plan of ranked insider buys, on a delay, with the plan archive
Start 7-day demoCard required. Your card is never charged for the demo.